CLINICAL TRIAL: BETA-AMYLOID PROBES OF ALZHEIMER'S DISEASE

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 我们的目的是测试3个假设：1）PET成像显示AD患者受AD影响的脑区中FDDNP浓度最高，MCI中浓度居中，年龄匹配的对照组中浓度最低。（2）FDDNP-PET和FDG-PET显像模式呈负相关。3)具有APOE-4的受试者比没有这种AD遗传风险的受试者具有更高的FDDNP脑浓度。 这些研究最终可能为1）早期症状前诊断和2）监测疾病进展和新型药物干预的疗效提供安全，有效和实用的方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our aim is to test 3 hypotheses: 1)PET imaging shows highest FDDNP concentrations in AD-affected brain regions in AD patients, intermediate concentrations in MCI, and lowest in age-matched controls. 2)FDDNP-PET and FDG-PET imaging patterns are inversely correlated. 3)Subjects with APOE-4 have greater FDDNP brain concentrations than those without this genetic risk for AD. These studies may eventually provide a safe, effective, and practical means for 1) early presymtomatic diagnosis, and 2) monitoring disease progression and efficacy of novel pharmacologic interventions.